PDS Biotechnology Corporation PDSB PHARMA
Company Overview
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -74.14% |
| 6 Months: | -56.20% |
| 3 Months: | -70.00% |
| 1 Month: | -61.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 79.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PDSB PDS Biotechnology Corporation PHARMA | 0.30 | -0.47 | $21.74M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.11M | 7.62M | 8.14M | 6.67M | 6.52M |
| Operating Income | -8.48M | -8.87M | -9.03M | -9.26M | -10.28M | -10.94M | -11.79M | -13.15M | -10.90M | -16.12M | -736.94K | -567.03K | -710.27K | -4.94M | -4.27M | -5.85M | -4.03M | -2.94M | -3.91M | -3.05M | -5.11M | -6.96M | - | -8.48M | -7.09M | -7.28M | - | -9.42M | -12.70M | -10.52M | - | -10.10M | -8.68M | -10.18M | - | -9.11M | -7.62M | -8.14M | -6.67M | -6.52M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.72M | -7.28M | -7.85M | -6.44M | -6.33M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 930.88K | 2.14M | 1.15M | 1.11M | 1.01M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.66M | -9.43M | -9.01M | -7.56M | -7.35M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.17M | 0 | 0 | 0 | 0 |
| Net Income | -10.13M | -7.96M | -9.17M | -9.38M | -10.76M | -9.52M | -12.17M | -13.50M | -11.28M | -13.90M | -737.89K | -567.83K | -711.21K | 6.82M | -3.89M | -5.75M | -3.99M | -2.93M | -3.91M | -3.05M | -588.93K | -6.96M | -6.32M | -8.47M | -5.82M | -7.42M | -19.14M | -9.66M | -11.53M | -10.85M | -10.90M | -10.60M | -8.33M | -10.73M | -7.95M | -8.49M | -9.43M | -9.01M | -7.56M | -7.35M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.39 | -0.19 | -0.21 | -0.14 | -0.03 | -0.24 | - | -0.32 | -0.20 | -0.26 | - | -0.32 | -0.37 | -0.35 | - | -0.30 | -0.23 | -0.29 | - | -0.21 | -0.21 | -0.19 | - | -0.13 |
| R&D Expense | 6.51M | - | 5.35M | 5.98M | 6.72M | - | 7.59M | 8.98M | 6.91M | - | 201.14K | 168.61K | 194.07K | 1.03M | 1.89M | 1.83M | 1.97M | 1.41M | 2.06M | 1.41M | 2.76M | 3.69M | - | 5.16M | 3.76M | 4.35M | - | 5.84M | 8.00M | 6.45M | - | 6.70M | 4.53M | 6.80M | - | 5.83M | 4.21M | 4.58M | - | 3.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 41.67M | 43.05M | 36.32M | 31.54M |
| Operating Income | -6.49M | -13.19M | -26.50M | -39.51M | -51.97M | -3.65M | -21.03M | -14.90M | -21.44M | -41.67M | -43.05M | -36.32M | -31.54M |
| EBITDA | - | - | - | - | - | - | - | - | - | -40.74M | -40.12M | -33.79M | -30.30M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 1.32M | 4.21M | 4.67M | 5.34M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -42.05M | -44.35M | -38.48M | -35.67M |
| Tax Provision | - | - | - | - | - | - | - | - | - | -1.20M | -1.41M | -869.17K | -1.17M |
| Net Income | -6.88M | -12.20M | -28.08M | -38.82M | -50.86M | -3.84M | -7.00M | -14.85M | -16.92M | -40.85M | -42.94M | -37.61M | -34.50M |
| Diluted EPS | - | - | - | - | - | - | - | -0.89 | -0.66 | -1.43 | -1.39 | -1.03 | -0.74 |
| R&D Expense | 4.48M | 8.47M | 17.84M | 24.83M | 34.31M | 830.74K | 6.10M | 7.92M | 11.25M | 29.43M | 27.76M | 22.57M | 19.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 16.85M | 134.09M | 110.91M | 92.62M | 164.43K | 14.49M | 30.89M | - | - | - | - | - | - | - | 77.01M | - | - | - | 59.39M | - | - | - | 45.36M | - | - | - | 30.49M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 76.48M | - | - | - | 59.06M | - | - | - | 45.05M | - | - | - | 28.25M |
| Cash & Equivalents | 140.93K | - | 7.86M | 13.73M | 130.19M | 106.40M | 88.07M | 103.69K | 12.16M | 28.84M | - | - | - | - | - | - | - | 73.82M | - | - | - | 56.56M | - | - | - | 41.69M | - | - | - | 26.71M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | 2.23M | 2.79M | 3.76M | - | - | - | - | - | - | - | 33.01M | - | - | - | 33.26M | - | - | - | 26.35M | - | - | - | 21.24M |
| Current Liabilities | - | - | - | 3.89M | 8.59M | 6.68M | 12.87M | 1.91M | 2.79M | 3.27M | - | - | - | - | - | - | - | 9.82M | - | - | - | 13.63M | - | - | - | 17.09M | - | - | - | 9.48M |
| Long Term Debt | - | - | - | - | 5.47M | - | - | - | - | - | - | - | - | - | - | - | - | 23.02M | - | - | - | 19.51M | - | - | - | 9.20M | - | - | - | 11.73M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.47M | - | - | - | 23.85M | - | - | - | 21.83M | - | - | - | 16.93M |
| Total Equity | - | -7.65M | -15.35M | -27.83M | 122.48M | 89.28M | -609.53K | -2.07M | 11.70M | 27.13M | 24.37M | 72.99M | 67.86M | - | 55.87M | 51.43M | 47.06M | 44.00M | 41.01M | 32.44M | 24.48M | 26.13M | 37.18M | 30.92M | 22.00M | 19.00M | 22.36M | 15.96M | 9.45M | 9.25M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.17M | - | - | - | 33.09M | - | - | - | 37.99M | - | - | - | 54.88M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -21.75M | -32.19M | -40.70M | -1.57M | -18.07M | -13.15M | - | -25.71M | -33.64M | -35.03M | -27.75M |
| Investing Cash Flow | - | - | -1.31M | -686.71K | -188.72K | 0 | 29.38M | 0 | - | - | 0 | -29.00K | 0 |
| Financing Cash Flow | - | - | 139.52M | 9.08M | 22.55M | 1.50M | 750.00K | 29.83M | - | 34.29M | 16.38M | 20.19M | 12.77M |
| Capital Expenditure | -136.89K | -884.79K | -1.31M | -686.71K | -188.72K | -0 | - | - | - | - | - | -29.00K | - |
| Free Cash Flow | - | - | -23.06M | -32.88M | -40.89M | -1.57M | - | - | - | -25.71M | -33.64M | -35.06M | -27.75M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | 8.58M | -17.26M | -14.87M | -14.98M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 44.8% | 43.8% | -22.9% | -43.5% | 8,344.1% | 185.7% | -59.8% | -54.7% | - | -92.8% | -164.3% | -197.9% | -372.9% |
| ROCE % | - | -101.9% | -21.1% | -37.9% | -65.2% | 209.0% | -179.8% | -54.0% | - | -62.0% | -94.1% | -128.5% | -150.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.04% | 1.70M | $1.37M |
| 2 | Focus Partners Wealth | 1.15% | 642.18K | $517.27K |
| 3 | Quantinno Capital Management, LP | 1.15% | 642.18K | $517.27K |
| 4 | Blackrock Inc. | 1.09% | 607.64K | $489.45K |
| 5 | Geode Capital Management, LLC | 1.05% | 587.14K | $472.94K |
| 6 | Vanguard Fiduciary Trust Co | 0.64% | 357.14K | $287.68K |
| 7 | Militia Capital Management LLC | 0.59% | 331.80K | $267.26K |
| 8 | Citadel Advisors Llc | 0.58% | 323.80K | $260.82K |
| 9 | Morgan Stanley | 0.56% | 313.92K | $252.86K |
| 10 | BLAIR WILLIAM & CO/IL | 0.54% | 300.00K | $241.65K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PDSB
80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOYm9tZzBUdnZscnlhT0tpd0NUZ3NfTmNLTFNjUFVyVEJmTWQ4WjV0TndTRVdnWUpUMkhrQW5CSENBano3WXJzVnotdmc5aGJibVNvZTR0STB4UDZkM2tQNjFmXzZlYnMtaENDamNjdXhYVmxKSDhnVUY3X29PY2JlSEpVV0wyQWhMLWxqbE…
Curious about the most active stocks on Tuesday? - ChartMill
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQQUhPMTRZUVlvRXdIaEUydnRGXzBVYWFOWXQycW0zdFVnRDIxNHhqcUVUb3JacnpNYlZRblZTR19GVXpNQkl2dUl5YTRaY3VvamJTYlQxU2xLLVVDc2U2aUU3THd1dnI5UmhWaDZxZW9pZXpQbzlxUWNnQ1VlYkF6eW9NcDZONnRrNnhIeG…
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNMHoyVzI0SXNuOW5NZUZnNnNFcmdoNTJWUGVyYk9TTTBqZmRaSERkM28yY2JKNE1McnpFb1ZrcVptNzN3Tzk2dVFTMDB4c19zdzU4aG9Ya1pLN1A0NzBhME9hOGlycFRwQkcyYWw0M2xyRURHMWdreVltdmR6Qlk4OEs4cVd0RFcxSVlSWV…
$PDS Biotechnology (PDSB.US)$ accumulating watch for vol 2-5x on 1 min when it breaks out - Moomoo
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxObmhZOWw1RzN0akZMREFZVkUtLWgwVm9UaHhka0tBUjRFSkczUXB3cURDWmJhQm1COHFiR0xJeWFKV1dkZUNrbjZ3TkphOTREVEZVbTkteDBxd21ZaW5EYm9iOE5oWGJhcUtJdDF1dVduUURZaE5odEZac0RfOFI0dF91dHJJVzZ0SWw4eG…
There are notable gap-ups and gap-downs in today's session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxONGpGbmR6bTVqUW8wbTlnZFl2OUJNSU1PbGNSLTVxSW5RVUpKMzZ2M1VOM2JNOTBZTHBjSkMwYU14WVhXakpLVThIWUs1MFNLZlNQUC1TUGhGRXBkZVJVWlNfSl8ybFlfcnRFV2xpUXFLNGhHdFl6QlF2anlwbV9WWTFyZC1MMEF5Yk91ZG…
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOM2E0M1JETUFsRjhBNXBCTXZPbHNUcXA0dm5MQjVrVHBGYXd0TmJxQmIzUFVaLVB1Y0hLU2FRaHlHa2tiTkhMVU80QTRyTGthUlpRd3g5V29OcGtUSzFJR0hpOEFvOVdCUHFHV3g4RzhHTXBFdjFwODk1MzZYZUN1VzZKR3pFc2JIUExkZE…
PDSB — Frequently Asked Questions
What is the current share price of PDS Biotechnology Corporation (PDSB)?
As of 2026-09-19 21:16 PDT, PDS Biotechnology Corporation (PDSB) trades at $0.30 on NasdaqCM. Its 52-week range is $0.20 to $1.43.
What is the market capitalisation of PDSB?
PDS Biotechnology Corporation (PDSB) has a market capitalisation of $21.74M on NasdaqCM.
What is the P/E ratio of PDSB?
PDSB trades at a trailing price-to-earnings (P/E) ratio of -0.47. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -12.59.
Is PDSB a good stock to buy?
This page provides a data-driven analysis of PDS Biotechnology Corporation (PDSB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.